Gilead, Abbott, Boehringer Ingelheim, Bristol-Myers, GlaxoSmithKline, J&J, Merck, Pfizer, Roche infectious news
California State Controller John Chiang sent letters to eight companies requesting they extend and expand existing supplemental price reduction and rebate program for its HIV/AIDS drugs with California's AIDS Drug Assistance Program (ADAP). The Controller said the state is not seeking a specific amount of cost savings for the program.
Drugs covered under the program include Kaletra lopinavir/ritonavir and Norvir ritonavir from Abbott; Aptivus tipranavir and Viramune nevirapine from Boehringer; Atripla emtricitabine/tenofovir/efavirenz and Truvada emtricitabine/tenofovir/rilpivirine from Gilead; Crixivan indinavir sulphate and Isentress raltegravir from Merck; Prezista darunavir from Johnson & Johnson; Epzicom abacavir/lamivudine and Combivir lamivudine/zidovudine from ViiV Healthcare LLC, a JV formed by GlaxoSmithKline and Pfizer; Reyataz atazanavir and Videx didanosine from Bristol-Myers; and Invirase saquinavir and Pegasys peginterferon alfa-2a from Roche. ...